Biotech
Freenome
Freenome raises $270M Series C at $1.1B valuation
$270M
Total Raised
Series C
Latest Round
2014
Founded
300+
Employees
South San Francisco, CA
1 min read
Quick Facts
Valuation
$1.1B
Latest Round Size
$270M
Latest Round Date
February 2021
Freenome: Series C Funding Round
Freenome has successfully raised $270M in Series C funding, reaching a valuation of $1.1B.
Company Overview
Early cancer detection using AI
Funding Details
The Series C round was led by T. Rowe Price, with participation from Perceptive Advisors.
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2014
- Employees: 300+
- Category: Biotech
Investment
Freenome plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- T. Rowe Price: Verified investor in Series C
- Perceptive Advisors: Verified investor in Series C
Key Investors
T. Rowe Price
Lead Investor
Verified investor in Series C
Perceptive Advisors
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Torl Biotherapeutics
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Editorial Team
Oct 10, 2025
1 min read•$96M
Biotech
Nilo Therapeutics
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Editorial Team
Oct 9, 2025
1 min read•$101M
Biotech
Arthrosi Therapeutics
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
Editorial Team
Oct 8, 2025
1 min read•$153M